IN2014CN04590A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN04590A IN2014CN04590A IN4590CHN2014A IN2014CN04590A IN 2014CN04590 A IN2014CN04590 A IN 2014CN04590A IN 4590CHN2014 A IN4590CHN2014 A IN 4590CHN2014A IN 2014CN04590 A IN2014CN04590 A IN 2014CN04590A
- Authority
- IN
- India
- Prior art keywords
- nucleic acid
- acid strand
- nucleotides
- nucleotide analogs
- transcription product
- Prior art date
Links
- 108020004707 nucleic acids Proteins 0.000 abstract 9
- 150000007523 nucleic acids Chemical class 0.000 abstract 9
- 102000039446 nucleic acids Human genes 0.000 abstract 9
- 125000003729 nucleotide group Chemical group 0.000 abstract 7
- 239000002773 nucleotide Substances 0.000 abstract 4
- 238000013518 transcription Methods 0.000 abstract 3
- 230000035897 transcription Effects 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 102100034343 Integrase Human genes 0.000 abstract 1
- 101710203526 Integrase Proteins 0.000 abstract 1
- 230000000692 anti-sense effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3181—Peptide nucleic acid, PNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/52—Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Saccharide Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011275488 | 2011-12-16 | ||
| PCT/JP2012/083180 WO2013089283A1 (en) | 2011-12-16 | 2012-12-17 | Chimeric double-stranded nucleic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN04590A true IN2014CN04590A (https=) | 2015-09-18 |
Family
ID=47559626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4590CHN2014 IN2014CN04590A (https=) | 2011-12-16 | 2012-12-17 |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US9816089B2 (https=) |
| EP (1) | EP2791335B1 (https=) |
| JP (7) | JP6112569B2 (https=) |
| CN (2) | CN112386605A (https=) |
| AU (1) | AU2012353330B2 (https=) |
| CA (2) | CA2859581C (https=) |
| ES (1) | ES2707232T3 (https=) |
| IN (1) | IN2014CN04590A (https=) |
| WO (1) | WO2013089283A1 (https=) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2767253A1 (en) | 2009-07-06 | 2011-01-13 | Ontorii, Inc. | Novel nucleic acid prodrugs and methods of use thereof |
| JP5868324B2 (ja) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
| AU2012284265B2 (en) | 2011-07-19 | 2017-08-17 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
| AU2012353330B2 (en) * | 2011-12-16 | 2018-04-19 | National University Corporation Tokyo Medical And Dental University | Chimeric double-stranded nucleic acid |
| SG11201500239VA (en) | 2012-07-13 | 2015-03-30 | Wave Life Sciences Japan | Asymmetric auxiliary group |
| CA2901983A1 (en) * | 2013-03-01 | 2014-09-04 | National University Corporation Tokyo Medical And Dental University | Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent |
| WO2014148620A1 (ja) * | 2013-03-21 | 2014-09-25 | 国立大学法人東京医科歯科大学 | 二重鎖核酸結合剤、当該結合剤－二重鎖核酸複合体、当該複合体を含有する医薬品組成物、及び、当該複合体の製造方法 |
| CN105324119A (zh) * | 2013-06-16 | 2016-02-10 | 国立大学法人东京医科齿科大学 | 具有外显子跳跃效应的双链反义核酸 |
| JP6482475B2 (ja) * | 2014-01-07 | 2019-03-13 | レナセラピューティクス株式会社 | アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド |
| US9714288B2 (en) | 2014-09-30 | 2017-07-25 | The Regents Of The University Of California | Antisense compounds and uses thereof |
| EP3277811B1 (en) | 2015-04-03 | 2020-12-23 | University of Massachusetts | Fully stabilized asymmetric sirna |
| US10633653B2 (en) | 2015-08-14 | 2020-04-28 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| EP3353306A4 (en) | 2015-09-25 | 2019-06-05 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| EP3366773A4 (en) * | 2015-10-23 | 2019-06-12 | Rena Therapeutics Inc. | NUCLEIC COMPLEX |
| WO2017068791A1 (ja) * | 2015-10-23 | 2017-04-27 | レナセラピューティクス株式会社 | 少なくとも１つのバルジ構造を有する核酸複合体 |
| WO2017094745A1 (ja) * | 2015-12-01 | 2017-06-08 | 国立大学法人大阪大学 | 核酸を含む経腸投与用組成物 |
| WO2017131124A1 (ja) * | 2016-01-26 | 2017-08-03 | 日産化学工業株式会社 | 一本鎖オリゴヌクレオチド |
| JP2019513371A (ja) | 2016-04-01 | 2019-05-30 | アビディティー バイオサイエンシーズ エルエルシー | 核酸ポリペプチド組成物とその使用 |
| EP3517610A4 (en) * | 2016-09-23 | 2020-05-27 | National University Corporation Tokyo Medical and Dental University | THROUGH HETERODUPLEX NUCLEIC ACID THROUGH BLOOD BRAIN CABINET |
| US11260134B2 (en) | 2016-09-29 | 2022-03-01 | National University Corporation Tokyo Medical And Dental University | Double-stranded nucleic acid complex having overhang |
| CN110337495B (zh) * | 2017-02-06 | 2024-03-29 | 日产化学株式会社 | 单链寡核苷酸 |
| WO2018181428A1 (ja) | 2017-03-29 | 2018-10-04 | 塩野義製薬株式会社 | 核酸医薬及び多分岐脂質の複合体 |
| WO2018180005A1 (ja) * | 2017-03-31 | 2018-10-04 | 国立研究開発法人日本医療研究開発機構 | コンドロイチン硫酸生合成を阻害するアンチセンス核酸 |
| WO2019004420A1 (ja) | 2017-06-30 | 2019-01-03 | 国立大学法人東京医科歯科大学 | ヘテロ二本鎖型ａｎｔｉｍｉＲ |
| AU2018307294B2 (en) * | 2017-07-26 | 2025-04-17 | Nissan Chemical Corporation | Single-stranded oligonucleotide |
| WO2019118916A1 (en) | 2017-12-14 | 2019-06-20 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| JP7360170B2 (ja) | 2018-02-28 | 2023-10-12 | 国立大学法人 東京医科歯科大学 | 虚血病変部位特異的な遺伝子治療法 |
| WO2019182294A1 (ko) * | 2018-03-19 | 2019-09-26 | 주식회사 케이티 | 비디오 신호 처리 방법 및 장치 |
| US11851654B2 (en) | 2018-03-19 | 2023-12-26 | National University Corporation Tokyo Medical And Dental University | Nucleic acid with reduced toxicity |
| MX2020009765A (es) | 2018-03-20 | 2021-01-08 | Tokyo Inst Tech | Oligonucleotido antisentido reducido en toxicidad. |
| JP7262816B2 (ja) * | 2018-03-22 | 2023-04-24 | 国立大学法人 東京医科歯科大学 | ヘテロ核酸のｂｂｂ通過脂質リガンド |
| CN113614232A (zh) | 2019-01-18 | 2021-11-05 | 马萨诸塞大学 | 动态药代动力学修饰锚 |
| EP3954395A4 (en) | 2019-04-08 | 2023-06-28 | National University Corporation Tokyo Medical and Dental University | Pharmaceutical composition for muscle disease treatment |
| WO2021020412A1 (ja) | 2019-07-30 | 2021-02-04 | 塩野義製薬株式会社 | Ｍｕｒｆ１を標的とする核酸医薬 |
| JP7793144B2 (ja) * | 2019-10-11 | 2026-01-05 | 国立大学法人東京科学大学 | 修飾ヘテロ核酸 |
| EP4090744A4 (en) * | 2020-01-17 | 2024-04-10 | Anastasia Khvorova | UNIVERSAL DYNAMIC PHARMACOKINETIC MODIFYING ANCHORS |
| EP4098747A4 (en) | 2020-01-31 | 2025-03-26 | Sanwa Kagaku Kenkyusho Co., Ltd. | ATN1 ANTISENSE OLIGONUCLEOTIDE |
| JPWO2021177418A1 (https=) | 2020-03-04 | 2021-09-10 | ||
| US20230174981A1 (en) | 2020-03-16 | 2023-06-08 | National University Corporation Tokyo Medical And Dental University | Heteronucleic acid containing morpholino nucleic acid |
| WO2021242883A1 (en) | 2020-05-26 | 2021-12-02 | University Of Massachusetts | Synthetic oligonucleotides having regions of block and cluster modifications |
| US12534493B2 (en) | 2020-06-15 | 2026-01-27 | Liid Pharmaceuticals, Inc. | Bridged nucleoside and nucleotide |
| WO2022106695A1 (en) | 2020-11-23 | 2022-05-27 | Alpha Anomeric Sas | Nucleic acid duplexes |
| WO2022183102A1 (en) * | 2021-02-26 | 2022-09-01 | Northwestern University | Cell-free biosensors with dna strand displacement circuits |
| US20240240183A1 (en) * | 2021-05-25 | 2024-07-18 | National University Corporation Tokyo Medical And Dental University | Heteronucleic acid containing scpBNA or AmNA |
| CA3222167A1 (en) | 2021-05-31 | 2022-12-08 | Rena Therapeutics Inc. | Ligand-binding nucleic acid complex |
| US20250339459A1 (en) * | 2021-08-19 | 2025-11-06 | National University Corporation Tokyo Medical And Dental University | Modified heteronucleic acid containing morpholino nucleic acid |
| US20240390508A1 (en) | 2021-08-21 | 2024-11-28 | Takeda Pharmaceutical Company Limited | Human transferrin receptor binding peptide-drug conjugate |
| WO2023042876A1 (ja) | 2021-09-15 | 2023-03-23 | 国立大学法人東京医科歯科大学 | ２'－修飾ヌクレオシドを含むヘテロ核酸 |
| US20250000892A1 (en) * | 2021-10-14 | 2025-01-02 | Arizona Board Of Regents On Behalf Of Arizona State University | Programmable delivery platforms for rna structures |
| JPWO2023080159A1 (https=) | 2021-11-02 | 2023-05-11 | ||
| WO2023105898A1 (ja) | 2021-12-07 | 2023-06-15 | リードファーマ株式会社 | アンチセンスオリゴヌクレオチド複合体 |
| JPWO2024071099A1 (https=) | 2022-09-29 | 2024-04-04 | ||
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| WO2024228398A1 (ja) * | 2023-05-02 | 2024-11-07 | 国立大学法人東京医科歯科大学 | グアニン四重鎖構造を誘導するための核酸剤 |
| WO2025047953A1 (ja) | 2023-08-30 | 2025-03-06 | 株式会社Stratoimmune | ＲａｓＧＲＰ４のアンチセンスオリゴヌクレオチド |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09110894A (ja) * | 1995-10-17 | 1997-04-28 | Soyaku Gijutsu Kenkyusho:Kk | ハイブリッドｄｎａ／ｒｎａオリゴヌクレオチド及び抗ウイルス剤 |
| US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| JP3781879B2 (ja) | 1996-11-18 | 2006-05-31 | 武 今西 | 新規ヌクレオチド類縁体 |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| AU9063398A (en) | 1997-09-12 | 1999-04-05 | Exiqon A/S | Oligonucleotide analogues |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US20060074034A1 (en) * | 2001-09-17 | 2006-04-06 | Collins Douglas A | Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof |
| FR2832154B1 (fr) * | 2001-11-09 | 2007-03-16 | Centre Nat Rech Scient | Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene |
| US20030104401A1 (en) | 2001-11-12 | 2003-06-05 | Epiclone, Inc. | Gene silencing using sense DNA and antisense RNA hybrid constructs |
| AU2003247521A1 (en) * | 2002-06-26 | 2004-01-19 | Isis Pharmaceuticals, Inc. | Antisense inhibition via rnase h-independent reduction in mrna |
| DE10240417A1 (de) | 2002-09-02 | 2004-03-11 | Avontec Gmbh | Decoy-Oligonukleotid-Hemmung der CD40-Expression |
| AU2003273336A1 (en) * | 2002-09-18 | 2004-04-08 | Isis Pharmaceuticals, Inc. | Efficient reduction of target rna's by single- and double-stranded oligomeric compounds |
| EP2336318B1 (en) | 2002-11-13 | 2013-04-24 | Genzyme Corporation | Antisense modulation of apolipoprotein b expression |
| EP1661905B9 (en) | 2003-08-28 | 2012-12-19 | IMANISHI, Takeshi | Novel artificial nucleic acids of n-o bond crosslinkage type |
| KR100750788B1 (ko) * | 2003-09-18 | 2007-08-20 | 아이시스 파마수티컬즈 인코포레이티드 | ｅＩＦ4Ｅ 발현의 조정 |
| US20050244869A1 (en) * | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
| AU2011204898A1 (en) * | 2004-04-09 | 2011-08-11 | Biodelivery Sciences International, Inc | Nucleotide-cochleate compositions and methods of use |
| WO2005113571A2 (en) * | 2004-05-13 | 2005-12-01 | The University Of North Carolina At Chapel Hill | Methods for the delivery of oligomeric compounds |
| WO2006074108A2 (en) * | 2004-12-30 | 2006-07-13 | Hauser Todd M | Compositions and methods for modulating gene expression using self-protected oligonucleotides |
| EP2023940B1 (en) | 2006-05-05 | 2011-06-22 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of sglt2 |
| WO2008018642A2 (en) * | 2006-08-10 | 2008-02-14 | Oncotherapy Science, Inc. | Genes and polypeptides relating to breast cancers |
| WO2008029619A1 (fr) | 2006-09-07 | 2008-03-13 | Daiichi Sankyo Company, Limited | Oligonucléotide antisens ena ayant une action spécifique de la séquence |
| ES2603379T3 (es) | 2006-10-09 | 2017-02-27 | Roche Innovation Center Copenhagen A/S | Compuestos antagonistas de ARN para la modulación de PCSK9 |
| US8093222B2 (en) * | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
| US7858592B2 (en) * | 2007-02-26 | 2010-12-28 | The Board Of Regents Of The University Of Texas System | Interfering RNAs against the promoter region of P53 |
| WO2008111908A1 (en) * | 2007-03-15 | 2008-09-18 | Jyoti Chattopadhyaya | Five- and six-membered conformationally locked 2',4'- carbocyclic ribo-thymidines for the treatment of infections and cancer |
| NZ587178A (en) * | 2008-02-08 | 2011-11-25 | Prosensa Holding Bv | Methods and means for treating dna repeat instability associated genetic disorders |
| EP2133425A1 (en) | 2008-06-13 | 2009-12-16 | Karin Mölling | Method and compound for antiviral (HIV) therapy |
| US8541569B2 (en) * | 2008-09-06 | 2013-09-24 | Chemgenes Corporation | Phosphoramidites for synthetic RNA in the reverse direction, efficient RNA synthesis and convenient introduction of 3'-end ligands, chromophores and modifications of synthetic RNA |
| US20130079382A1 (en) * | 2009-10-12 | 2013-03-28 | Larry J. Smith | Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro |
| AU2012353330B2 (en) * | 2011-12-16 | 2018-04-19 | National University Corporation Tokyo Medical And Dental University | Chimeric double-stranded nucleic acid |
| ES2700277T3 (es) * | 2013-05-30 | 2019-02-14 | Univ Nat Corp Tokyo Medical & Dental | Agentes de doble cadena para el suministro de oligonucleótidos terapéuticos |
-
2012
- 2012-12-17 AU AU2012353330A patent/AU2012353330B2/en active Active
- 2012-12-17 IN IN4590CHN2014 patent/IN2014CN04590A/en unknown
- 2012-12-17 JP JP2014528740A patent/JP6112569B2/ja active Active
- 2012-12-17 CN CN202011292547.5A patent/CN112386605A/zh active Pending
- 2012-12-17 CA CA2859581A patent/CA2859581C/en active Active
- 2012-12-17 EP EP12815856.5A patent/EP2791335B1/en active Active
- 2012-12-17 WO PCT/JP2012/083180 patent/WO2013089283A1/en not_active Ceased
- 2012-12-17 CN CN201280062110.XA patent/CN104126010B/zh active Active
- 2012-12-17 CA CA3106312A patent/CA3106312C/en active Active
- 2012-12-17 ES ES12815856T patent/ES2707232T3/es active Active
-
2014
- 2014-06-13 US US14/303,989 patent/US9816089B2/en active Active
-
2017
- 2017-03-08 JP JP2017044034A patent/JP6416301B2/ja active Active
- 2017-10-05 US US15/725,845 patent/US10337006B2/en active Active
-
2018
- 2018-06-28 US US16/021,165 patent/US10329567B2/en active Active
- 2018-10-03 JP JP2018188022A patent/JP6638923B2/ja active Active
-
2019
- 2019-05-13 US US16/410,803 patent/US11034955B2/en active Active
- 2019-12-12 JP JP2019224279A patent/JP6960123B2/ja active Active
-
2020
- 2020-10-27 JP JP2020179738A patent/JP7174384B2/ja active Active
-
2021
- 2021-05-27 US US17/332,249 patent/US12344841B2/en active Active
- 2021-08-24 JP JP2021136038A patent/JP2022000426A/ja active Pending
-
2022
- 2022-09-15 JP JP2022146970A patent/JP7423015B2/ja active Active
-
2023
- 2023-12-21 US US18/392,869 patent/US20240158790A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014CN04590A (https=) | ||
| HK1221978A1 (zh) | Tmprss6 irna组合物及其使用方法 | |
| IN2013MN00522A (https=) | ||
| MY201125A (en) | Novel promoter and method for producing purine nucleotide using the same | |
| EP3693464A3 (en) | Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes | |
| WO2010080129A3 (en) | Extended dicer substrate agents and methods for the specific inhibition of gene expression | |
| NZ593618A (en) | Gnaq targeted dsrna compositions and methods for inhibiting expression | |
| NZ627060A (en) | Polynucleotide molecules for gene regulation in plants | |
| WO2011123621A3 (en) | 2' and 5' modified monomers and oligonucleotides | |
| WO2012142611A3 (en) | Sequencing small amounts of complex nucleic acids | |
| SG170780A1 (en) | Compositions and methods for inhibiting expression of eg5 gene | |
| WO2012046085A3 (en) | Methods of inducing insulin production | |
| SG10201804076RA (en) | Methods for multiplex detection of alleles associated with ophthalmic conditions | |
| NZ601247A (en) | Targeted genomic alteration | |
| EP4269584A3 (en) | Selective antisense compounds and uses thereof | |
| JP2012050447A5 (https=) | ||
| TN2015000079A1 (en) | Antisense polynucleotides to induce exon skipping and methods of treating dystrophies | |
| WO2012168307A3 (en) | Improved recombination efficiency by inhibition of nhej dna repair | |
| WO2013010062A3 (en) | Nucleic acid complexity reduction | |
| WO2012078967A3 (en) | Compositions and methods for increasing erythropoietin (epo) production | |
| WO2010006973A3 (en) | Compositions and methods for inhibiting expression of tgf-beta receptor genes | |
| WO2012115454A3 (ko) | 뉴클레아제에 의해 유전자 변형된 세포를 농축시키는 방법 | |
| Cortez et al. | microRNAs in cancer: from bench to bedside | |
| WO2007147067A8 (en) | Methods and compositions for regulating cell cycle progression | |
| WO2009086428A3 (en) | Methods and compositions for increasing gene expression |